川芎嗪联合血栓通治疗缺血性脑卒中的效果分析

Analysis of the effect of ligustrazine combined with Xueshuantong in the treatment of ischemic stroke

目的分析川芎嗪联合血栓通治疗缺血性脑卒中的临床效果。方法80例缺血性脑卒中患者,采用计算机按照随机双盲原则分为对照组和联合组,各40例。对照组采用奥扎格雷治疗,联合组采用川芎嗪联合血栓通治疗。比较两组临床疗效、复发率、不良反应发生率及治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、日常生活活动能力量表(Barthel指数)评分、超敏C反应蛋白水平、血液流变学指标。结果联合组患者治疗总有效率为92.50%(37/40),高于对照组的72.50%(29/40),差异有统计学意义(P<0.05)。治疗后,两组患者NIHSS评分低于治疗前,Barthel指数评分高于治疗前,且联合组患者NIHSS评分(10.25±3.47)分明显低于对照组的(16.69±3.17)分,Barthel指数评分(87.65±8.02)分明显高于对照组的(63.54±7.24)分,差异有统计学意义(P<0.05)。治疗后,两组患者全血高切粘度和全血低切粘度均低于治疗前,且联合组患者全血高切粘度(4.91±0.87)mPa·s和全血低切粘度(8.04±1.39)mPa·s均低于对照组的(5.86±0.93)、(10.35±1.65)mPa·s,差异有统计学意义(P<0.05)。治疗后,两组患者超敏C反应蛋白水平均明显低于治疗前,且联合组患者超敏C反应蛋白(12.09±3.14)mg/L明显低于对照组的(7.02±2.14)mg/L,差异有统计学意义(P<0.05)。联合组患者不良反应发生率5.00%及复发率2.50%均明显低于对照组的20.00%、22.50%,差异有统计学意义(P<0.05)。结论脑卒中患者采用川芎嗪联合血栓通治疗可以有效提高临床效果,改善神经功能及生活质量,减少复发率,安全性高,值得临床推广。

Objective To analyze the clinical effect of ligustrazine combined with Xueshuantong in the treatment of ischemic stroke.Methods A total of 80 patients with ischemic stroke were divided into a control group and a combination group according to computerized randomized double-blind principle,with 40 cases in each group.Patients in the control group were treated with Ozagrel,and those in the combination group were treated with ligustrazine combined with Xueshuantong.Both groups were compared in terms of clinical efficacy,recurrence rate,incidence of adverse reactions,and changes in National Institutes of Health Stroke Scale(NIHSS)score,activities of daily living scale(Barthel index)score,high-sensitivity C-reactive protein level,and hemorheology index before and after treatment.Results The total effective rate of treatment for patients in the combination group was 92.50%(37/40),which was higher than 72.50%(29/40)in the control group,and the difference was statistically significant(P<0.05).After treatment,the NIHSS scores in both groups were lower than those before treatment in this group,and the Barthel index scores were higher than those before treatment in this group;the NIHSS score(10.25±3.47)points in the combination group was significantly lower than(16.69±3.17)points in the control group;the Barthel index score(87.65±8.02)points in the combination group was significantly higher than(63.54±7.24)points in the control group;the differences were all statistically significant(P<0.05).After treatment,the whole blood high-shear viscosity and whole blood low-shear viscosity of both groups were lower than those of this group before treatment;the whole blood high-shear viscosity(4.91±0.87)mPa·s and whole blood low-shear viscosity(8.04±1.39)mPa·s in the combination group were lower than(5.86±0.93)and(10.35±1.65)mPa·s of the control group;the differences were all statistically significant(P<0.05).After treatment,the high-sensitivity C-reactive protein in both groups was significantly lower than those before treatment in this group,and the high-sensitivity C-reactive protein(12.09±3.14)mg/L in the combination group was significantly lower than(7.02±2.14)mg/L in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 5.00% and recurrence rate 2.50% in the combination group were significantly lower than 20.00% and 22.50%in the control group,and the differences were all statistically significant(P<0.05).Conclusion Treatment of stroke patients with ligustrazine and Xueshuantong can effectively improve clinical effect,improve neurological function and quality of life,reduce recurrence rate with high safety,which is worthy of clinical promotion.